The first full week of November delivers a broad and high-impact earnings lineup across semiconductors, cloud software, AI, ...

A stunning new study offers early evidence that Covid-19 vaccines might have a secret superpower: a precisely timed mRNA shot ...

Moderna is down 35.3% since the beginning of the year, and at $27.16 per share, it is trading 50.3% below its 52-week high of ...

Recently, Zacks.com users have been paying close attention to Moderna (MRNA). This makes it worthwhile to examine what the stock has in store.

Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

Durban-headquartered pharmaceutical major Aspen Pharmacare confirmed in a Sens announcement on Friday that it has reached a ...

Moderna ($MRNA) stock jumped 17% on Thursday, fueled by speculation of potential buyout talks amid concerns over declining ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

The democratization of investing started with discount brokers slashing commissions and advanced through no-transaction-fee ...

Novartis is buying Avidity Biosciences in an all-cash deal valued at $12 billion to access Avidity's experimental treatments for neuromuscular diseases.

Stock futures edged higher on Monday as optimism over a potential US-China trade deal and a widely expected Federal Reserve ...

Avidity Biosciences (RNA) shares surged as much as 45% in premarket trading on Monday after Novartis (NVS) agreed to buy the biotechnology company in a deal valued at $12 billion.